Mood Stabilizers and Treatment Adherence in Bipolar Disorder: Addressing Adverse Events

References

• Connelly CE, Davenport YB, Nurnberger JI, Jr.: Adherence to treatment regimen in a lithium carbonate clinic. Arch Gen Psychiatry 1982; 39:585–588
   Google Scholar
• Maj M. Pirozzi R. Magliano L, Bartoli L: Long-term outcome of lithium prophylaxis in bipolar disorder: A 5-year prospec-tive study of 402 patients at a lithium clinic. Am I Psychiatry 1998; 155:30–35
   Google Scholar
• Suppes T. Baldessarini RJ, Faedda GL, Tondo L, Tohen M. Discontinuation of maintenance treatment in bipolar disorder: Risks and implications. Harv Rev Psychiatry 1993; 1:131–144
   Google Scholar
• Tondo L, Baldessarini RI; Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000; 61(Suppl 9):97–104
   PubMedGoogle Scholar
• Tondo L, Hennen J, Baldessarini RJ: Lower suicide risk with long-term lithium treatment in major affective illness: A meta-analysis. Acta Psychiatr Scand 2001; 104:163–172
   PubMed Web of Science ®Google Scholar
• Maj M, Pirozzi R, Magliano L: Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: Prevalence and predictors. Am J Psychiatry 1995; 152:1810–1811
   PubMed Web of Science ®Google Scholar
• Schou M: The combat of non-compliance during prophylactic lithium treatment. Acta Psychiatr Scand 1997; 95:361–363
   PubMed Web of Science ®Google Scholar
• Scott J, Pope M: Nonadherence with mood stabilizers: Preva-lence and predictors. J Clin Psychiatry 2002; 63:384–390
   PubMed Web of Science ®Google Scholar
• Lingam R, Scott J: Treatment non-adherence in affective dis-orders. Acta Psychiatr Scand 2002; 105:164–172
   PubMed Web of Science ®Google Scholar
• Johnson RE, McFarland BH: Lithium use and discontinuation in a health maintenance organization. Am J Psychiatry 1996; 153:993–1000
   PubMed Web of Science ®Google Scholar
• Nilsson A, Axelsson R: Factors associated with discontinu-ation of long-term lithium treatment. Acta Psychiatr Scand 1989; 80:221–230
   Google Scholar
• Peet M, Harvey NS: Lithium maintenance: 1. A standard edu-cation programme for patients. Br J Psychiatry 1991; 158:197–200
   Google Scholar
• Sachs GS, Guille C: Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999; 60(Suppl 21):16–19
   PubMed Web of Science ®Google Scholar
• Mendlewicz J, Souery D, Rivelli SK: Short-term and long-term treatment for bipolar patients: Beyond the guidelines. J Affect Disord 1999; 55:79–85
   Google Scholar
• Zarate CA, Jr.: Antipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry 2000; 61(Suppl 8):52–61
   PubMed Web of Science ®Google Scholar
• Cheskin U, Bartlett SJ, Zayas R, Twilley CH, Allison DB, Contoreggi C: Prescription medications: A modifiable contrib-utor to obesity. South Med J 1999; 92:898–904
   PubMedGoogle Scholar
• McElroy SL, Frye MA, Suppes T, Dhavale D, Keck PE, Jr., Leverich GS, Altshuler L, Denicoff KD, Nolen WA, Kupka R, Grunze H, Walden J, Post RM: Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63:207–213
   PubMed Web of Science ®Google Scholar
• Fakhoury WK, Wright D, Wallace M: Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline, lot Clin Psychopharmacol 2001; 16:153–162
   Google Scholar
• Gitlin MJ, Cochran SD, Jamison KR: Maintenance lithium treatment: Side effects and compliance. J Clin Psychiatry 1989; 50:127–131
   PubMed Web of Science ®Google Scholar
• Garland EJ, Remick RA, Zis AP: Weight gain with antidepres-sants and lithium. J Clin Psychopharmacol 1988; 8:323–330
   PubMed Web of Science ®Google Scholar
• Corman CL, Leung NM, Guberman AH: Weight gain in epileptic patients during treatment with valproic acid: A ret-rospective study. Can J Neurol Sci 1997; 24:240–244
   PubMedGoogle Scholar
• Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A. Petty F. Pope HG, Jr., Schou JC, Keck PE, Jr., Rhodes U. Swann AC, Hirschfeld RM, Wozniak PJ: A randomized. placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57:481–489
   Google Scholar
• Coxhead N. Silverstone T, Cookson J: Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992: 85:114–118
   Google Scholar
• Betts T. Goodwin G, Withers RM, Yuen AW: Human safety of lamotrigine. Epilepsia 1991; 32(Suppl 2):S17–S21
   Google Scholar
• Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS: Weight change associated with valproate and lam-otrigine monotherapy in patients with epilepsy. Neurology 2001:56:172–177
   PubMed Web of Science ®Google Scholar
• Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Locatelli G, Leverich GS, Post RM: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607–614
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Rathore D, Levine J, Atzert R, Solai L, Parepally H, Levin H, Moffa N, Delaney J, BrarJS: Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1:42–53
   PubMedGoogle Scholar
• Chengappa KNR, Levine J, Rathore D, Parepally H, Atzert R: Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: A case-series. Eur Psy-chiatry 2001; 16:186–190
   Google Scholar
• Holt RA, Maunder EMW: Is lithium-induced weight gain pre-vented by providing health eating advice at commencement of lithium therapy? J Hum Nutr Diet 1996; 9:127–133
   Google Scholar
• Ball MP, Coons VB, Buchanan RW: A program for treating olanzapine-related weight gain. Psychiatr Serv 2001; 52:967–969
   PubMed Web of Science ®Google Scholar
• Pen MG: Maintenance effects in the long-term management of obesity. Clin Psychol Sci Pract 1998; 5:526–543
   Google Scholar
• Zimmermann U, Rechlin T, Plaskacewicz GJ, Barocka A, Wildt L, Kaschka WP: Effect of naltrexone on weight gain and food craving induced by tricyclic antidepressants and lithium: An open study. Biol Psychiatry 1997; 41:747–749
   Google Scholar
• Floris M, Lejeune J, Deberdt W: Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsy-chopharmacol 2001; 11:181–182
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: Amer-ican Psychiatric Publishing; 1994
   Google Scholar
• Sacchetti E, Guarneri L, Bravi D: H(2) antagonist niza-tidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000; 48:167–168
   PubMed Web of Science ®Google Scholar
• Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG: Ef-ficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271:918–924
   PubMed Web of Science ®Google Scholar
• Zarate CA, Jr., Tohen M, Narendran R, Tomassini EC, McDonald J, Sederer M, Madrid AR: The adverse effect pro-file and efficacy of divalproex sodium compared with valproic acid: A pharmacoepidemiology study. J Clin Psychiatry 1999; 60:232–236
   PubMed Web of Science ®Google Scholar
• Persson G: Lithium side effects in relation to dose and to levels and gradients of lithium in plasma. Acta Psychiatr Scand 1977; 55:208–213
   Google Scholar
• Persson G: Plasma lithium levels and side effects during ad-ministration of a slow release lithium sulphate preparation (Lithium lipett C) and lithium carbonate tablets. Acta Psy-chiatr Scand 1974; 50:174–182
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1–50
   Web of Science ®Google Scholar
• Stoll A, Vuckovic A, McElroy SL: Histamine-2-receptor an-tagonists for the treatment of valproate-induced gastrointesti-nal distress. Ann Clin Psychiatry 1991; 3:301–304
   Google Scholar
• Baldessarini RJ: Lithium salts and antimanic agents. In: Chemotherapy in Psychiatry: Principles and Practice. Cam-bridge, MA: Harvard University Press; 1985:93–127
   Google Scholar
• Lenox RH, Manji HK: Lithium. In: Schatzberg AE Nemeroff CB, eds. The American Psychiatric Press Textbook of Psy-chopharmacology. Washington, DC: American Psychiatric Press; 1995:303–349
   Google Scholar
• Lyskowski J. Nasrallah HA: Slowed release lithium: A review and a comparative study. J Clin Psychopharmacol 1981; 1:406–408
   Google Scholar
• Arana GW, Hyman SE, Rosenbaum JF: Mood stabilizers. In: Handbook of Psychiatric Drug Therapy. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:114–143
   Google Scholar
• Goodwin FK, Jamison KR: Manic-Depressive Illness. New York: Oxford University Press; 1990
   Google Scholar
• Judd LL, Hubbard B, Janowsky DS, Huey LY, Attewell PA: The effect of lithium carbonate on affect, mood, and person-ality of normal subjects. Arch Gen Psychiatry 1977; 34:346–351
   PubMed Web of Science ®Google Scholar
• Judd LL, Hubbard B, Janowsky DS, Huey LY, Takahashi KI: The effect of lithium carbonate on the cognitive functions of normal subjects. Arch Gen Psychiatry 1977; 34:355–357
   PubMed Web of Science ®Google Scholar
• Clark L, Iversen SD, Goodwin GM: Sustained attention deficit in bipolar disorder. Br J Psychiatry 2002; 180:313–319
   PubMed Web of Science ®Google Scholar
• Prohaska ML, Stern RA, Mason GA, NeveIs CT, Prange AJ: Thyroid hormones and lithium-related neuropsycholog-ical deficits: A preliminary test of the lithium-thyroid interac-tive hypothesis. J Int Neuropsychol Soc 1995; 1:134
   Google Scholar
• Prohaska ML, Stern RA, NeveIs CT, Mason GA, Prange AJ: The relationship between thyroid status and neuropsycho-logical performance in psychiatric outpatients maintained on lithium. Neuropsychiatry Neuropsychol Behav Neurol 1996; 9:30–34
   Google Scholar
• Joffe RT, Levitt AJ: Major depression and subclinical (grade 2) hypothyroidism. Psychoneuroendocrinology 1992; 17:215–221
   PubMed Web of Science ®Google Scholar
• Frye MA, Denicoff 1CD, Bryan AL, Smith-Jackson EE, Ali SO, Luckenbaugh D, Leverich GS, Post RM: Association between lower serum free T4 and greater mood instability and depres-sion in lithium-maintained bipolar patients. Am J Psychiatry 1999156:1909-1914
   PubMedGoogle Scholar
• Hirschfeld RMA, Bowden CL, Perlis RH, Gitlin MJ, Suppes T, Keck PE, Thase ME: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159:1–50
   Web of Science ®Google Scholar
• Stoll AL, Locke CA, Vuckovic A, Mayer PV: Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: A case series. J Clin Psychiatry 1996; 57:356–359
   PubMed Web of Science ®Google Scholar
• Goldberg IF, Burdick KE: Cognitive side effects of anticon-vulsants, J Clin Psychiatry 2001; 62\(Suppl 14):27–33
   Google Scholar
• Martin R, Kuzniecky R, Ho S, Hetherington H, Pan J, Sinclair K, Gilliam F, Faught E: Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurol-ogy 1999; 52:321–327
   PubMed Web of Science ®Google Scholar
• Crawford 13: An audit of topiramate use in a general neu-rology clinic. Seizure 1998; 7: 207–211
   Google Scholar
• Ketter TA. Post RM, Theodore WH: Positive and negative psy-chiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53:S53–S67
   PubMed Web of Science ®Google Scholar
• Macritchie KAN, Geddes JR, Scott J, Haslam DRS, Goodwin GM: Valproic acid, valproate adn divalproex in the mainte-nance treatment of bipolar disorder. Cochrane Libr, Oxford 2001; 3:1–26
   Google Scholar
• Gelenberg AJ, Jefferson JW: Lithium tremor. J Clin Psychiatry 1995; 56:283–287
   PubMed Web of Science ®Google Scholar
• Miodownik C, Witztum E, Lerner V: Lithium-induced tremor treated with vitamin B6: A preliminary case series. Int J Psy-chiatry Med 2002; 32:103–108
   PubMed Web of Science ®Google Scholar
• Maj M, Starace F, Nolfe G. Kemali D: Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar dis-order: A prospective study. Pharmacopsychiatry 1986; 19:420–423
   Google Scholar
• Gelenberg AJ, Kane JM, Keller MB, Lavori P. Rosenbaum JF, Cole K, Lavelle J: Comparison of standard and low serum lev-els of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321:1489–1493
   PubMed Web of Science ®Google Scholar
• Vestergaard P: How does the patient prefer his lithium treat-ment? Pharmacopsychiatry 1985; 18:223–224
   Google Scholar
• Zaninelli R, Bauer M, Jobert M. Muller-Oerlinghausen B: Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. J Clin Psychopharmacol 2001; 21:190–198
   Google Scholar
• Lapierre YD: control of lithium tremor with propranolol. Can Med Assoc J 1976; 114:619-620,624
   Google Scholar
• Zubenko GS, Cohen BM, Lipinski IF, Jr.: Comparison of meto-prolol and propranolol in the treatment of lithium tremor. Psy-chiatry Res 1984; 11:163–164
   Google Scholar
• Karas BJ, Wilder BJ, Hammond ES, Bauman AW: Treatment of valproate tremors. Neurology 1983; 33:1380–1382
   PubMed Web of Science ®Google Scholar
• Karas BJ, Wilder BJ, Hammond EJ, Bauman AW: Valproate tremors. Neurology 1982; 32:428–432
   PubMed Web of Science ®Google Scholar
• Lamictal product information: Based on: Physicians' Desk Reference, 56th edn. 2002
   Google Scholar
• Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E: Lamotrigine-associated rash: Risk/benefit considerations in adults and children. Epilepsia 1999; 40:985–991
   PubMed Web of Science ®Google Scholar
• Wong ICK, Lhatoo SD: Adverse reactions to new anticonvul-sant drugs. Drug Saf 2000; 23:35–56
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK, Frye MA, Kusumakar V: Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management. J Clin Psychiatry 2002; 63:1012–1019
   PubMed Web of Science ®Google Scholar
• Depakote product information: Based on: Physicians' Desk Reference, 56th edn. 2002
   Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J. Solomon DA, Leon AC, Rice JA, Keller MB: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59:530–537
   Google Scholar
• Ketter TA, Calabrese JR: Stabilization of mood from below versus above baseline in bipolar disorder: A new nomencla-ture. J Clin Psychiatry 2002; 63:146–151
   PubMed Web of Science ®Google Scholar
• Seltzer A. Roncari I, Garfinkel P: Effect of patient education on medication compliance. Can .1 Psychiatry 1980; 25: 638–645
   Google Scholar
• Clarkin IF, Carpenter D, Hull J, Wittier P. Glick I: Effects of psychoeducational intervention for married patients with bipolar disorder and their spouses. Psychiatr Serv 1998:49:531–533
   PubMed Web of Science ®Google Scholar
• Cochran SD: Preventing medical noncompliance in the outpa-tient treatment of bipolar affective disorders. J Consult Clin Psychol 1984; 52:873–878
   PubMed Web of Science ®Google Scholar
• Lam DI-1, Bright J. Jones S. Hayward P, Schuck N, Chisolm D. Sham P: Cognitive therapy for bipolar illness---A pilot study of relapse prevention. Cogn Ther Res 2002:24: 503–520
   Google Scholar
• Dunner DL: Optimizing lithium treatment. J Clin Psychiatry 2000; 61(Suppl 9):76–81
   Google Scholar
• Janicak PG, Davis JM, Preskorn SH, Ayd Fir Treatment with mood stabilizers: Management of an acute manic episode. In: Gay S. ed. Principles and Practice of Psychopharmacotherapy. Baltimore, MD: Williams & Wilkins; 1997:412–428
   Google Scholar
• Janicak PG, Davis ..IM, Preskorn SH, Ayd El: Treatment with mood stabilizers: Maintenance/prophylaxis. In: Gay S. ed. Principles and Practice of Psychopharmacotherapy. Baltimore, MD: Williams & Wilkins; 1997:428–441
   Google Scholar
• Janicak PG, Davis JM, Preskorn SH. Ayd Fir Adverse effects of lithium and valproate. In: Gay S. ed. Principles and Practice of Psychopharmacotherapy. Baltimore, MD: Williams & Wilkins: 1997:461–468
   Google Scholar
• Lavantes B, Senimon F, Bayle FJ: Compliance with and toler-ance of sustained-release lithium carbonate. Encephale 1999; 25:152–157
   Google Scholar